Dermatology · Chicago area, IL
Dermatology and skin studies in Chicago area, IL
23 recruiting studies have a site in the Chicago area. This page includes nearby cities such as Evanston, Oak Brook, Oak Lawn, Park Ridge.
23 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingPhase 2
A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis
Apogee Therapeutics, Inc.
- Location
- Skokie, IL + 22 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata
Pfizer
- Location
- Chicago, IL + 28 other US sites
- Eligibility basics
- Ages 12+
- RecruitingPhase 2
A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
Sanofi
- Location
- Skokie, IL + 19 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata.
Pfizer
- Location
- Skokie, IL + 18 other US sites
- Eligibility basics
- Ages 6–14
- RecruitingPhase 3
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines
Takeda
- Location
- Orland Park, IL + 45 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 1
Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in Pediatric Participants With Juvenile Psoriatic Arthritis (JPsA).
Novartis Pharmaceuticals
- Location
- Chicago, IL + 10 other US sites
- Eligibility basics
- Ages 2–17
- RecruitingPhase 3
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
Bristol-Myers Squibb
- Location
- Skokie, IL + 90 other US sites
- Eligibility basics
- Ages 40+
- RecruitingPhase 2
A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
Novartis Pharmaceuticals
- Location
- Glenview, IL + 23 other US sites
- Eligibility basics
- Ages 18–99
- RecruitingPhase 3
An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS
Novartis Pharmaceuticals
- Location
- Glenview, IL + 20 other US sites
- Eligibility basics
- Ages 18–100
- RecruitingPhase 3
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
Incyte Corporation
- Location
- Chicago, IL + 73 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
Incyte Corporation
- Location
- Skokie, IL + 23 other US sites
- Eligibility basics
- Ages 12–17
- RecruitingPhase 3
A Study to Investigate Efficacy, Safety and Tolerability of Barzolvolimab Versus Placebo in Adults With Cold Induced Urticaria and Symptomatic Dermographism Inadequately Controlled by H1-antihistamines (EMBARQ - ColdU…
Celldex Therapeutics
- Location
- Skokie, IL + 24 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
Study of Remibrutinib (LOU064) Efficacy and Safety and Exploration of Its Mechanism of Action in Participants With Chronic Urticaria
Novartis Pharmaceuticals
- Location
- Glenview, IL + 1 other US site
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis
Enveda Therapeutics
- Location
- Chicago, IL + 29 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 2
ORKA-002 Versus Placebo in Participants With Moderate-to-Severe Hidradenitis Suppurativa
Oruka Therapeutics, Inc.
- Location
- Chicago, IL + 13 other US sites
- Eligibility basics
- Ages 18–79
- RecruitingPhase 2
An Outpatient Study of the Efficacy of ARS-2 in Patients With Chronic Spontaneous Urticaria
ARS Pharmaceuticals, Inc.
- Location
- Glenview, IL + 1 other US site
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo
Incyte Corporation
- Location
- Chicago, IL + 65 other US sites
- Eligibility basics
- Ages 2–11
- RecruitingPhase 3
A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata
Eli Lilly and Company
- Location
- Skokie, IL + 28 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 1/Phase 2
Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Adults With Moderate to Severe Acne
Sanofi Pasteur, a Sanofi Company
- Location
- Chicago, IL + 78 other US sites
- Eligibility basics
- Ages 18–45
- RecruitingPhase 1
A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults
UCB Biopharma SRL
- Location
- Chicago, IL + 29 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata
Sun Pharmaceutical Industries, Inc.
- Location
- Chicago, IL + 53 other US sites
- Eligibility basics
- Ages 12–17
- RecruitingPhase 2
Study of Targeted Therapies for the Treatment of Adult Participants With Active Psoriatic Arthritis
AbbVie
- Location
- Skokie, IL + 14 other US sites
- Eligibility basics
- Ages 18+
- RecruitingHealthy volunteers
The Gut and Skin Microbiome in Vitiligo Disease Progression
Northwestern University
- Location
- Chicago, IL
- Eligibility basics
- Ages 18–89
Who these studies look for
Most require an active, diagnosed skin condition of a certain severity and a pause on some current treatments before starting.
Matching a page like this one never means you qualify. Each research team decides eligibility at screening.